CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma.
CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma.
复制标题
DOI：
10.1186/1756-9966-31-59
复制
发表时间：
2012-07-04
期刊：
影响因子：
--
通讯作者：
Sun Q
中科院分区：
文献类型：
--
作者：
Lin Y;Zhong Y;Guan H;Zhang X;Sun Q
浸润性导管癌是最常见的乳腺恶性肿瘤类型，具有不同的分子特征和对治疗的抗性。虽然CD 44 +/CD 24-细胞被认为是乳腺癌干细胞，并与一些患者的预后不良有关，但这些细胞与所有或某些类型的浸润性导管癌的肿瘤复发或转移之间的关系尚不清楚。共147例随机选择的原发性和继发性浸润性导管癌样本进行了CD 44、CD 24、ER、PR和Her 2的表达测定。评估这些患者的CD 44 +/CD 24-肿瘤细胞比例与临床病理特征之间的关系。CD 44 +/CD 24-肿瘤细胞在70.1%的肿瘤中检出，中位数比例为5.8%。CD 44 +/CD 24-肿瘤细胞的比例与淋巴结受累（P = 0.026）和PR状态（P = 0.038）显著相关，并且与复发或转移性肿瘤患者的强PR状态（P = 0.046）和基底样特征（P = 0.05）相关。有和无CD 44 +/CD 24-/low肿瘤细胞患者的中位无病生存期（DFS）分别为22.9 ± 2.2个月和35.9 ± 3.8个月，有和无CD 44 +/CD 24-/low肿瘤细胞患者的中位总生存期（OS）分别为39.3 ± 2.6个月和54.0 ± 3.5个月，单因素和多因素分析均显示CD 44 +/CD 24-/low肿瘤细胞比例与DFS和OS密切相关。浸润性导管癌中CD 44 +/CD 24-肿瘤细胞的患病率差异很大，在PR状态高的原发性肿瘤和继发性肿瘤中，这种表型的发生率较高。此外，这种表型与较短的累积DFS和OS显著相关。因此，CD 44 +/CD 24-表型可能是浸润性导管癌患者手术切除和化疗后恶性复发的重要因素。
Invasive ductal carcinoma is the most common type of breast malignancy, with varying molecular features and resistance to treatment. Although CD44+/CD24- cells are believed to act as breast cancer stem cells and to be linked to poor prognosis in some patients, the association between these cells and tumor recurrence or metastasis in all or some types of invasive ductal carcinoma is unclear. A total of 147 randomly selected primary and secondary invasive ductal carcinoma samples were assayed for expression of CD44, CD24, ER, PR, and Her2. The association between the proportions of CD44+/CD24- tumor cells and the clinico-pathological features of these patients was evaluated. CD44+/CD24- tumor cells were detected in 70.1% of the tumors, with a median proportion of 5.8%. The proportion of CD44+/CD24- tumor cells was significantly associated with lymph node involvement (P = 0.026) and PR status (P = 0.038), and was correlated with strong PR status in patients with recurrent or metastatic tumors (P = 0.046) and with basal-like features (p = 0.05). The median disease-free survival (DFS) of patients with and without CD44+/CD24-/low tumor cells were 22.9 ± 2.2 months and 35.9 ± 3.8 months, and the median overall survival (OS) of patients with and without CD44+/CD24-/low tumor cells were 39.3 ± 2.6 months and 54.0 ± 3.5 months, respectively, and with both univariate and multivariate analyses showing that the proportion of CD44+/CD24-/low tumor cells was strongly correlated with DFS and OS. The prevalence of CD44+/CD24- tumor cells varied greatly in invasive ductal carcinomas, with the occurrence of this phenotype high in primary tumors with high PR status and in secondary tumors. Moreover, this phenotype was significantly associated with shorter cumulative DFS and OS. Thus, the CD44+/CD24- phenotype may be an important factor for malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma.
登录
查看更多内容
DOI：
10.1186/bcr2773
发表时间：
2010
期刊：
Breast cancer research : BCR
影响因子：
--
作者：
Louie E;Nik S;Chen JS;Schmidt M;Song B;Pacson C;Chen XF;Park S;Ju J;Chen EI
通讯作者：
Chen EI
影响因子：
7.4
作者：
Fillmore, Christine M.;Kuperwasser, Charlotte
通讯作者：
Kuperwasser, Charlotte
影响因子：
7.4
作者：
Sheridan, Carol;Kishimoto, Hiromitsu;Fuchs, Robyn K.;Mehrotra, Sanjana;Bhat-Nakshatri, Poornima;Turner, Charles H.;Goulet, Robert, Jr.;Badve, Sunil;Nakshatri, Harikrishna
通讯作者：
Nakshatri, Harikrishna
影响因子：
45.3
作者：
Voduc, K. David;Cheang, Maggie C. U.;Kennecke, Hagen
通讯作者：
Kennecke, Hagen
影响因子：
158.5
作者：
Liu, Rui;Wang, Xinhao;Clarke, Michael F.
通讯作者：
Clarke, Michael F.